Browse News
Filter News
Found 2,989 articles
-
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
4/18/2024
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Biopharmaceutical Fermentation Market Size Expected to Reach USD 16.03 Billion to 2031
4/17/2024
Global Biopharmaceutical Fermentation Market is valued at US$ 10.17 Bn in 2023, and it is expected to reach US$ 16.03 Bn by 2031, with a CAGR of 6.11% during the forecast period of 2024-2031.
-
Cell-Free RNA Isolation and Extraction Kits Market Reach USD123.94 Million by 2031
4/17/2024
Global Cell-Free RNA Isolation & Extraction Kits Market is valued at US$ 41.55 Mn in 2023, and it is expected to reach US$ 123.94 Mn by 2031, with a CAGR of 14.90% during the forecast period of 2024-2031.
-
RNA Analysis Transcriptomics Market to reach over USD 42.4 billion by the year 2031
4/16/2024
Global RNA Analysis Transcriptomics Market is valued at US$ 11.26 Bn in 2023, and it is expected to reach US$ 42.43 Bn by 2031, with a CAGR of 18.30% during the forecast period of 2024-2031.
-
The global contract development and manufacturing organization is investing $1.2 billion to boost production capabilities at its Holly Springs, North Carolina, site including mammalian cell culture bioreactors.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.
-
Microbiology Testing Market Experiencing Rapid Growth
4/1/2024
The global microbiology testing market size was valued at USD 5.33 billion in 2023 and it is expected to surpass around USD 12.72 billion by 2033 with a CAGR of 9.12% from 2024 to 2033 due to the increasing demand for genetic testing services.
-
Automated Cell Counter Market Experiencing Rapid Expansion
4/1/2024
The global automated cell counter market size was valued at USD 6.48 billion in 2023 and it is projected to surpass around USD 11.20 billion by 2033 with a CAGR of 5.62% from 2024 to 2033.
-
Pharmaceutical Market Size to Hit Around USD 2,832.66 Bn by 2033
3/28/2024
According to Vision Research Reports, the global pharmaceutical market size was estimated at USD 1,559.53 billion in 2023 and it is expected to surpass around USD 2,832.66 billion by 2033.
-
Genetic Analysis Market Size to Attain Around USD 23.60 BN by 2033
3/28/2024
The global genetic analysis market was evaluated at USD 10.55 billion in 2023 and is expected to attain around USD 23.60 billion by 2033
-
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
3/26/2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that on March 26, 2024, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYLOY™ (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
-
The PD-1 inhibitor Keytruda significantly improved overall survival in a late-stage trial when used with chemoradiotherapy to treat patients with newly diagnosed advanced cervical cancer.
-
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3/7/2024
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
-
Columvi (glofitamab for injection) receives positive CADTH and INESSS recommendations for adult patients with relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL)
3/7/2024
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on March 5, 2024, the Institut National d'Excellence en Santé et en Services Sociaux (INESSS) recommended Columvi® (glofitamab for injection) for public reimbursement.
-
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
2/29/2024
Lineage Cell Therapeutics, Inc. today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets.
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2/28/2024
Repare Therapeutics Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
2/28/2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2023 and provided guidance for 2024.